Programs

The journey to create KRAS inhibitors has been ongoing for over three decades.^1,2  Our experienced team is rigorously advancing discovery and development programs targeting the KRAS^G12C, KRAS^G12D and other KRAS mutations.

Checkpoint inhibitors (CPI) have revolutionized the cancer treatment landscape by helping many people with different types of cancer live longer. Over time, patients have progression of their disease on or after receiving CPI therapy, leaving them with few remaining treatment options.

Our research is investigating whether novel combination approaches will augment CPI therapy by targeting key pathways and cell types responsible for tumor growth and immune suppression in the tumor microenvironment.

MRTX1719 is an investigational, internally discovered synthetic lethal PRMT5 inhibitor for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.